Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Testing Status of AZT+3TC+NVP combination M000049

 

CASRN: AZT3TCCOMBO

Synonyms/Common Names

  • AZT + 3TC (Lamivudine) + NVP (Nevirapine)

Secondary:

  • 134678-17-4 - 3TC (AIDS initiative)
  • 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
  • 30516-87-1 - AZT transplacental carcinogenesis study
  • 129618-40-2 - Nevirapine

Known Uses

Special combination to study AIDS therapeutics

Short-Term Toxicity

  • 28 days (Gavage)  (C20310B)  Completed 
    • Mice: C3B6F1-+/TRP53<TM1BRD> (NCTR)
    • Dose: 0, 80, 160, or 240 mg/kg bwt.

Long-Term Carcinogenicity

  • 45 weeks (Gavage)  (C20310B)  Completed 
    • GMM-16 (NIH Number: 14-5973)  (Peer Review Approval 02/00/2012A )
      Toxicology and Carcinogenicity Study of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CASRNs 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53tm1Brd N12 Haploinsufficient Mice (In Utero and Postnatal Gavage Studies)
    • Mice: C3B6F1-+/TRP53<TM1BRD> (NCTR)
    • Dose: 25 animals/group; dose combinations AZT, 3TC, NVP, AZT/3TC, AZT/3TC/NVP.

Genetic Toxicology

  • Micronucleus  (A40581)  Completed 
    • Mice: Swiss CD-1
    • Male Positive 
    • Female NA 
  • Micronucleus  (A62246)  Completed 
    • Mice: Swiss CD-1
    • Male Negative 
  • Micronucleus  (A62527)  Completed 
    • Mice: Swiss CD-1
    • Male Negative 
  • Micronucleus  (A75317)  Completed 
    • Mice: Swiss CD-1
    • Male Positive 
  • Micronucleus  (A78223)  Completed 
    • Mice: Swiss CD-1
    • Male Negative 
  • Micronucleus  (A83804)  Completed 
    • Mice: Swiss CD-1
    • Male Positive 

Organ Systems Toxicity

  • 2nd generation Continuous Breeding (Legacy) (Gavage)  (RACB20204)  Completed 
    • Male and Female Mice: Swiss CD-1
    • Dose: 0, 25/50, 35.5/75, 50/100, OR 75/150 MG/KG/DAY.
  • 6 to 16 GD Conventional Teratology (Gavage)  (TER20203)  Completed 
    • Citation: Developmental Toxicity Evaluation of 3'-Azido-3'-deoxythymidine (AZT; CASRN 30516-87-1) and (-) 2', 3'-Dideoxy-3'-thiacytidine (3TC; CASRN 134678-17-4) Co-administered by Gavage to Swiss Albino (CD-1®) Mice on Gestational Days 6 through 16
    • Citation: Developmental Toxicity Evaluation of 3'-Azido-3'-deoxythymidine (AZT; CASRN 30516-87-1) and (-)2',3'-Dideoxy-3'-thiacytidine (3TC; CASRN 134678-17-4) Co-administered by Gavage to Swiss Albino (CD-1®) Mice on Gestational Days 6 Through 16
    • Female Mice: Swiss CD-1
    • Dose: 0/0, 0/50, 0/100, 0/200, 0/1000, 100/0, 200/0, 400/0, 100/50, 200/100, 400/200 AND 400/1000 MG/KG/DAY (AZT/3TC).
  • 6 to 16 GD Teratology Pilot Studies (Gavage)  (TRP20202)  Completed 
    • Female Mice: Swiss CD-1
    • Dose: 0/0, 0/200, 0/1000, 100/50, 200/100, 400/0, 400/200, 400/400, OR 400/1000 AZT/3TC MG/KG/DAY.